All In Biotech

Drug Trial Radar · NCT05987033

Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.

A First-in-human Proof-of-concept Study With NVDX3, an Osteogenic Implant of Human Allogenic Origin, in the Treatment of Distal Radius Fractures in Adults.

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

11

Actual

Start

Aug 8, 2023

Primary completion

Dec 19, 2024

Study completion Dec 19, 2024

Sponsor

Lead sponsor
Novadip BiosciencesIndustry
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.

Conditions

  • Distal Radius Fractures

Interventions

  • NVDX3Drug

    NVDX3 is implanted during a single surgical intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Serious Treatment-emergent Adverse Events (TEAEs) and NVDX3-related TEAEsTime frame: Between the beginning of the implant surgery (IS) and 12 months post-IS

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier de Luxembourg

    Luxembourg, Luxembourg

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.